Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BEIGENE NZ UNLIMITED,Tislelizumab,"Advanced non-small cell lung cancer, 2nd line monotherapy irrespective of PDL-1 status",Tislelizumab (Tevimbra),,Hospital,
